secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-054726
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics reduces workforce by 67% after suspending HSCT-TMA program
-----------------------------------------------------------------------------

- Workforce reduction of ~67% implemented May 1, 2024; includes elimination of senior management positions.
- Expected severance and related costs $3.1–3.2M, including ~$1.6M non-cash equity vesting; costs payable through Q4 2024.
- Board member Rachelle Jacques resigned May 7, 2024; board reduced to five members with no disagreement reported.
- Reduction is part of restructuring to cut HSCT-TMA operating costs and support long-term strategic plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/0000950170-24-054726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/aktx-20240501.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer